4 years ago

Invizius Secures £5.3M Series A Funding for Innate Immune Response Treatments

  • Invizius Limited, a biotechnology company, has closed a £5.3 million Series A financing round led by existing investors Mercia, Downing Ventures, and others

  • The funds will be used to complete a clinical study of its H-Guard Priming Solution to reduce inflammatory effects of haemodialysis.

      • ProblemHealthcare

      "reducing the life-threatening inflammatory effects of dialysis"

      Solution

      "developing a novel protein that lines the inside of the dialysis filter, helping dialysis to take place undetected by the body’s immune system, thereby suppressing the blood’s foreign body response and preventing a hostile inflammatory reaction"

      Covered on